诺唯赞(688105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688105 诺唯赞

交易中 09-24 13:52:56

{"stockData":{"symbol":"688105","market":"SH","secType":"STK","nameCN":"诺唯赞","latestPrice":22.69,"timestamp":1758693176000,"preClose":21.68,"halted":0,"volume":3203897,"delay":0,"changeRate":0.0466,"floatShares":398000000,"shares":398000000,"eps":-0.0783,"marketStatus":"交易中","change":1.01,"latestTime":"09-24 13:52:56","open":21.65,"high":22.74,"low":21.54,"amount":71378700,"amplitude":0.0554,"askPrice":22.7,"askSize":65,"bidPrice":22.69,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.0783,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1758697200000},"marketStatusCode":2,"adr":0,"adjPreClose":21.68,"symbolType":"stock_kcb","openAndCloseTimeList":[[1758677400000,1758684600000],[1758690000000,1758697200000]],"highLimit":23.85,"lowLimit":19.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":397734544,"isCdr":false,"pbRate":2.24,"roa":"--","roe":"0.08%","epsLYR":-0.05,"committee":-0.312169,"marketValue":9025000000,"turnoverRate":0.0081,"status":0,"floatMarketCap":9025000000},"requestUrl":"/m/hq/s/688105","defaultTab":"news","newsList":[{"id":"2565545543","title":"每周股票复盘：诺唯赞（688105）首次回购股份4.00万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2565545543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565545543?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:56","pubTimestamp":1757192172,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，诺唯赞报收于23.19元，较上周的24.4元下跌4.96%。本周，诺唯赞9月1日盘中最高价报24.61元。公司公告汇总：截至2025年8月31日，诺唯赞累计回购股份数量为0万股，尚未实施回购。公司公告汇总诺唯赞于2025年9月1日首次通过集中竞价交易方式回购股份，回购数量为4.00万股，占公司总股本397,734,544股的0.01%。减持期间为2025年9月24日至2025年12月23日，任意连续90日内集中竞价减持不超过总股本1%，大宗交易不超过2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2564262801","title":"诺唯赞最新公告：持股5%以上股东国寿成达拟减持不超过3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2564262801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564262801?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:40","pubTimestamp":1756813216,"startTime":"0","endTime":"0","summary":"诺唯赞(688105.SH)公告称，股东国寿成达计划通过大宗交易及集中竞价的方式减持公司股份合计不超过11,932,036股，即不超过公司总股本的3%，自减持计划公告披露之日起15个交易日后的3个月内进行。其中，通过集中竞价方式减持的，任意连续90日内减持总数不超过公司股份总数的1%；通过大宗交易方式减持的，任意连续90日内减持总数不超过公司股份总数的2%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200035002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2564801603","title":"诺唯赞：股东国寿成达拟减持不超3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801603","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564801603?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:38","pubTimestamp":1756813118,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688105"],"gpt_icon":0},{"id":"2563839980","title":"每周股票复盘：诺唯赞（688105）中报净利降80.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563839980","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563839980?lang=zh_cn&edition=full","pubTime":"2025-08-31 11:25","pubTimestamp":1756610713,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，诺唯赞报收于24.4元，较上周的25.95元下跌5.97%。本周，诺唯赞8月26日盘中最高价报26.36元。本周关注点业绩披露要点：诺唯赞2025年中报归母净利润312.94万元，同比下降80.63%。股本股东变化截至2025年6月30日，诺唯赞股东户数为8,596户，较3月31日增加199户，增幅2.37%。公司公告汇总南京诺唯赞生物科技股份有限公司2025年半年度报告摘要披露，公司总资产52.41亿元，较上年度末增长3.81%；归属于上市公司股东的净资产38.49亿元，较上年度末下降2.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100003253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2563006247","title":"诺唯赞出资882万元成立南京诺泰赞生物制药有限公司，持股44.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563006247","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563006247?lang=zh_cn&edition=full","pubTime":"2025-08-30 10:06","pubTimestamp":1756519607,"startTime":"0","endTime":"0","summary":"天眼查工商信息显示，近日，南京诺唯赞生物科技股份有限公司出资882万元成立南京诺泰赞生物制药有限公司，持股44.1%，所属行业为医药制造业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/30100652824903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","688105"],"gpt_icon":0},{"id":"2563070324","title":"诺唯赞（688105）2025年中报简析：净利润同比下降80.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563070324","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563070324?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:14","pubTimestamp":1756505697,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺唯赞发布2025年中报。根据财报显示，诺唯赞净利润同比下降80.63%。截至本报告期末，公司营业总收入6.06亿元，同比下降6.63%，归母净利润312.94万元，同比下降80.63%。按单季度数据看，第二季度营业总收入3.21亿元，同比下降7.61%，第二季度归母净利润121.95万元，同比下降88.86%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000010525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105"],"gpt_icon":0},{"id":"2562175038","title":"图解诺唯赞中报：第二季度单季净利润同比下降88.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562175038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562175038?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:19","pubTimestamp":1756376396,"startTime":"0","endTime":"0","summary":"证券之星消息，诺唯赞2025年中报显示，公司主营收入6.06亿元，同比下降6.63%；归母净利润312.94万元，同比下降80.63%；扣非净利润-3314.25万元，同比下降116.7%；其中2025年第二季度，公司单季度主营收入3.21亿元，同比下降7.61%；单季度归母净利润121.95万元，同比下降88.86%；单季度扣非净利润-1134.87万元，同比下降1824.33%；负债率26.59%，投资收益137.56万元，财务费用142.54万元，毛利率69.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800035290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105"],"gpt_icon":0},{"id":"2562908259","title":"诺唯赞(688105)6月30日股东户数0.86万户，较上期增加2.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562908259","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562908259?lang=zh_cn&edition=full","pubTime":"2025-08-28 17:26","pubTimestamp":1756373217,"startTime":"0","endTime":"0","summary":"证券之星消息，近日诺唯赞披露，截至2025年6月30日公司股东户数为8596.0户，较3月31日增加199.0户，增幅为2.37%。在生物制品行业个股中，诺唯赞股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年3月31日至2025年6月30日，诺唯赞区间跌幅为6.33%，在此期间股东户数增加199.0户，增幅为2.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800033107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2562908972","title":"诺唯赞：拟与艺妙神州设立合资公司 合作开发阿尔茨海默病筛查及细胞治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2562908972","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562908972?lang=zh_cn&edition=full","pubTime":"2025-08-28 16:47","pubTimestamp":1756370861,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4022","688105","BK0216","AD","BK4575","BK4132","BK4230","CAR","MSC","BK4150"],"gpt_icon":0},{"id":"2558074575","title":"南京诺唯赞生物科技股份有限公司中标喀斯玛商城采购订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2558074575","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558074575?lang=zh_cn&edition=full","pubTime":"2025-08-10 02:52","pubTimestamp":1754765522,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年08月08日，南京诺唯赞生物科技股份有限公司中标喀斯玛商城发布的采购订单[250709361055701]，中标金额为298.0元。采购订单内容显示，成交商品包括2 × Rapid Taq Master Mix和SwiftCut NotⅠ，分别以单价118.00元和180.00元成交，合计金额298.00元。此次采购涉及的部门为生物与制药学院。公告类型为其他。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081002523994d9e7d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081002523994d9e7d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","159837","688105"],"gpt_icon":0},{"id":"2558501459","title":"诺唯赞中标中山眼科中心项目 券商看好公司未来发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2558501459","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558501459?lang=zh_cn&edition=full","pubTime":"2025-08-09 18:39","pubTimestamp":1754735982,"startTime":"0","endTime":"0","summary":"2025年08月09日，据天眼查数据，中山眼科中心诺唯赞0.2mlPCR8联管（含平盖）显示，中标方为诺唯赞，招标方为中山眼科中心。近半年内，诺唯赞获得5家券商积极评价：中泰证券和国盛证券给予\"买入\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报24.71元，下跌0.56%，成交额至6844.26万元。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809183951a47ea78c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809183951a47ea78c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2558014515","title":"诺唯赞中标1.30万元 券商积极评价彰显成长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2558014515","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558014515?lang=zh_cn&edition=full","pubTime":"2025-08-09 18:39","pubTimestamp":1754735940,"startTime":"0","endTime":"0","summary":"2025年08月09日，据天眼查数据，生命科学学院RecJfExonuclease试剂显示，中标方为诺唯赞，招标方为生命科学学院，金额1.30万元。近半年内，诺唯赞获得5家券商积极评价：中泰证券和国盛证券给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报24.71元，下跌0.56%，成交额至6844.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809183906a6dc65dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809183906a6dc65dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688105"],"gpt_icon":0},{"id":"2557552984","title":"诺唯赞中标医学院项目 券商积极评级彰显发展潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2557552984","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557552984?lang=zh_cn&edition=full","pubTime":"2025-08-07 18:32","pubTimestamp":1754562720,"startTime":"0","endTime":"0","summary":"2025年08月07日，据天眼查数据，医学院诺唯赞2×PhantaMaxMasterMix显示，中标方为诺唯赞，招标方为医学院。近半年内，诺唯赞获得5家券商积极评价：东吴证券和中金公司给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报24.85元，下跌1.19%，成交额至6960.89万元。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807183205a6d89722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807183205a6d89722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688105"],"gpt_icon":0},{"id":"2557552959","title":"诺唯赞中标中山医学院项目 券商积极评级彰显成长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2557552959","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557552959?lang=zh_cn&edition=full","pubTime":"2025-08-07 18:31","pubTimestamp":1754562709,"startTime":"0","endTime":"0","summary":"近半年内，诺唯赞获得5家券商积极评价：东吴证券和中金公司给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报24.85元，下跌1.19%，成交额至6960.89万元。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807183153a47abf6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807183153a47abf6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688105"],"gpt_icon":0},{"id":"2557393520","title":"诺唯赞中标中山医学院项目 券商积极评价提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2557393520","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557393520?lang=zh_cn&edition=full","pubTime":"2025-08-05 18:37","pubTimestamp":1754390254,"startTime":"0","endTime":"0","summary":"近半年内，诺唯赞获得5家券商积极评价：国盛证券和中泰证券给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报25.11元，下跌0.32%，成交额至7388.06万元。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805183742a6d4560f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805183742a6d4560f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2556879631","title":"生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时","url":"https://stock-news.laohu8.com/highlight/detail?id=2556879631","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556879631?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:00","pubTimestamp":1754236800,"startTime":"0","endTime":"0","summary":"近期重磅BD 交易总结艾伯维和罗氏先后在2025 年一季度花重金布局amylin 分子。艾伯维将支付首付款3.5 亿美金，里程碑高达18.75 亿美金，以及销售分成。高质量减重方面，临床前DIO 大鼠数据显示Eloralintide 减少的体重最高达91%为脂肪。而目前GLP-1 类药物减重中约20%-40%为瘦体重。此外，礼来在ADA 大会上表示未来不排除eloralintide 开发月度制剂的可能性。Metsera 公司明确MET-223i 将定位为月度制剂。值得指出的是，Structure 和众生药业以小分子形式切入了amylin 赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688443","688488","688137","688293","688319","603590","688163","688105","688739","603392","600739","600161","688177","688687","688336","BK0239","603087","688276","600211","688278","600867","688670","688166","688520"],"gpt_icon":0},{"id":"2556829522","title":"每周股票复盘：诺唯赞（688105）计划回购500万至1000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2556829522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556829522?lang=zh_cn&edition=full","pubTime":"2025-08-03 03:44","pubTimestamp":1754163853,"startTime":"0","endTime":"0","summary":"截至2025年8月1日收盘，诺唯赞报收于25.03元，较上周的25.03元上涨0.0%。本周，诺唯赞7月29日盘中最高价报26.44元。公司将严格按照相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080300000638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688105","BK0216"],"gpt_icon":0},{"id":"2556197823","title":"诺唯赞中标化学学院项目 券商积极评级彰显成长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2556197823","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556197823?lang=zh_cn&edition=full","pubTime":"2025-08-02 18:42","pubTimestamp":1754131357,"startTime":"0","endTime":"0","summary":"近半年内，诺唯赞获得5家券商积极评价：东吴证券和国盛证券给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报25.03元，下跌0.2%，成交额至9276.49万元。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802184242a6cf3063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802184242a6cf3063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688105"],"gpt_icon":0},{"id":"2556893434","title":"诺唯赞：尚未实施股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2556893434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556893434?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:51","pubTimestamp":1754034704,"startTime":"0","endTime":"0","summary":"格隆汇8月1日丨诺唯赞(688105.SH)公布，截至2025年7月31日，公司尚未实施股份回购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801155208972c5463&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801155208972c5463&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688105"],"gpt_icon":0},{"id":"2555046695","title":"诺唯赞中标中山医学院项目 券商积极评价彰显成长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2555046695","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555046695?lang=zh_cn&edition=full","pubTime":"2025-07-30 19:07","pubTimestamp":1753873678,"startTime":"0","endTime":"0","summary":"2025年07月30日，据天眼查数据，中山医学院诺唯赞10μlPipetteTips显示，中标方为诺唯赞，招标方为中山医学院。近半年内，诺唯赞获得5家券商积极评价：中泰证券和东吴证券给予\"买入\"评级。西部证券给予\"增持\"评级。诺唯赞主营业务涵盖生物试剂，诊断试剂，仪器设备，其他收入之和。截至发稿，诺唯赞股价报25.39元，下跌3.97%，成交额至1.36亿元。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730190800a46b7c9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730190800a46b7c9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688105"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758693192762,"stockEarnings":[{"period":"1week","weight":-0.0466},{"period":"1month","weight":-0.1645},{"period":"3month","weight":-0.0217},{"period":"6month","weight":-0.093},{"period":"1year","weight":0.2884},{"period":"ytd","weight":-0.0157}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.001},{"period":"3month","weight":0.1059},{"period":"6month","weight":0.1328},{"period":"1year","weight":0.3903},{"period":"ytd","weight":0.1402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京诺唯赞生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"8596人(较上一季度增加2.37%)","perCapita":"46269股","listingDate":"2021-11-15","address":"江苏省南京市栖霞区经济技术开发区科创路红枫科技园C1-2栋东段1-6层","registeredCapital":"39773万元","survey":"　　南京诺唯赞生物科技股份有限公司的主营业务是酶、抗原、抗体等生物制品的研发、生产和销售。公司的主要产品是生物试剂、POCT诊断试剂和仪器。截至2025年6月30日，公司共获得121项发明专利授权，发明专利申请累计269项。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺唯赞(688105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺唯赞(688105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺唯赞,688105,诺唯赞股票,诺唯赞股票老虎,诺唯赞股票老虎国际,诺唯赞行情,诺唯赞股票行情,诺唯赞股价,诺唯赞股市,诺唯赞股票价格,诺唯赞股票交易,诺唯赞股票购买,诺唯赞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺唯赞(688105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺唯赞(688105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}